This study focuses on patients with anti-MAG neuropathy, a rare nerve condition that causes weakness and numbness in the arms and legs. The condition is associated with the presence of specific antibodies that damage the protective covering of nerves. The study will test the effectiveness of rituximab, a medication that targets certain immune system cells, compared to placebo in treating this condition.

The purpose of this research is to determine if rituximab can improve neurological function in people with anti-MAG neuropathy who are likely to respond well to the treatment. The study will last 12 months, during which participants will receive either rituximab or placebo through intravenous infusion. The treatment will be given along with sodium chloride solution, which helps deliver the medication into the bloodstream.

Throughout the study, doctors will monitor changes in participants’ nerve function and ability to perform daily activities. They will assess walking ability, hand function, and nerve signals to evaluate how well the treatment is working. The study will also track the levels of harmful antibodies in the blood and any side effects that may occur during treatment.